The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 921-927 , November 2009

Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma

  • Tmirah Haselkorn, PhD

      Affiliations

    • Genentech, Inc, South San Francisco, Calif
    • Corresponding Author InformationReprint requests: Tmirah Haselkorn, PhD, Genentech, Inc, 1 DNA Way, MS 58B, South San Francisco, CA 94080.
    • ,
  • Robert S. Zeiger, MD, PhD

      Affiliations

    • Kaiser-Permanente Medical Center, San Diego, Calif
    • ,
  • Bradley E. Chipps, MD

      Affiliations

    • Capital Allergy and Respiratory Disease Center, Sacramento, Calif
    • ,
  • David R. Mink, MS

      Affiliations

    • ICON Clinical Research, San Francisco, Calif
    • ,
  • Stanley J. Szefler, MD

      Affiliations

    • National Jewish Health, Denver, Colo
    • ,
  • F. Estelle R. Simons, MD

      Affiliations

    • University of Manitoba, Winnipeg, Manitoba, Canada
    • ,
  • Marc Massanari, PharmD

      Affiliations

    • Novartis Pharmaceuticals Corp, East Hanover, NJ
    • ,
  • James E. Fish, MD

      Affiliations

    • Genentech, Inc, South San Francisco, Calif

Received 1 April 2009 ,Revised 22 August 2009 ,Accepted 3 September 2009.

  • Image Result

    Model I diagram. ∗Many covariates were collected annually and not semiannually, requiring that the covariates be defined only at baseline (BL), 12 months, and 24 months.

    Model I diagram. ∗Many covariates were collected annually and not semiannually, requiring that the covariates be defined only at baseline (BL), 12 months, and 24 months.

  • Image Result

    Model II diagram. ∗Many covariates were collected annually and not semiannually, requiring that the covariates be defined only at baseline (BL), 12 months, and 24 months.

    Model II diagram. ∗Many covariates were collected annually and not semiannually, requiring that the covariates be defined only at baseline (BL), 12 months, and 24 months.

  • Image Result

    Predictors of future exacerbations.

    Predictors of future exacerbations.

 Support for third-party medical writing assistance was provided by Genentech USA, Inc, and Novartis Pharmaceuticals Corp.

 Disclosure of potential conflict of interest: T. Haselkorn is a consultant for Genentech. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering-Plough and has received research support from AstraZeneca, Merck, GlaxoSmithKline, TEVA, Aerocrine, and the National Heart, Lung, and Blood Institute. B. E. Chipps is an advisor and/or speakers' bureau member for Alcon, Aventis, Genentech, AstraZeneca, Boehringer, GlaxoSmithKline, MedPoint, Novartis, Pfizer, Schering, Sepracor, and Merck and has received support for research and/or educational activities from Alcon, Aventis, Genentech, AstraZeneca, GlaxoSmithKline, MedPoint, Novartis, Schering, Sepracor, and Merck. D. R. Mink is an employee of ICON Clinical Research, which receives research funding from Genentech. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, and Merck and has received research support from the National Institutes of Health, the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases, Ross Pharmaceuticals, and GlaxoSmithKline. F. E. R. Simons has received research support from the Canadian Institutes of Health Research and has consulted for Genentech. M. Massanari is an employee of Novartis. J. E. Fish is an employee of Genentech.

PII: S0091-6749(09)01335-9

doi: 10.1016/j.jaci.2009.09.006

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 921-927 , November 2009

Article Tools

* Image Usage & Resolution